



June 11, 2014

## Alder BioPharmaceuticals to Present at Two Conferences in June

BOTHELL, Wash., June 11, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing therapeutic antibodies for the treatment of migraine, autoimmune and inflammatory diseases, today announced that members of Alder's senior management team will present at two upcoming conferences in June:

- **Wells Fargo Securities 2014 Healthcare Conference**

**Date:** Tuesday, June 17, 2014

**Time:** 4:40 p.m. EDT

**Location:** Boston, MA

- **Washington Biotechnology & Biomedical Association (WBBA) 14<sup>th</sup> Annual Life Science Innovation Northwest**

**Date:** Thursday, June 19, 2014

**Time:** 1:45 p.m. PDT

**Location:** Seattle, WA

A live webcast of the Wells Fargo Healthcare Conference presentation can be accessed from the Investors section of the Alder website at <http://www.alderbio.com>. An archived replay of the webcast will be available on Alder's website for 30 days after the live event concludes.

### About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's wholly-owned therapeutic program, an investigational monoclonal antibody for migraine, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is now undergoing clinical testing. Alder plans to advance ALD403 into a Phase IIb trial in the second half of 2014. Clazakizumab, previously known as ALD518, is Alder's investigational monoclonal antibody to the pro-inflammatory cytokine IL-6. Bristol-Myers Squibb is investigating Clazakizumab (as BMS-945429) in a Phase IIb clinical study in rheumatoid arthritis and other autoimmune indications based on a 2009 partnership. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. For more information, please visit <http://www.alderbio.com>.

CONTACT: Media Contacts:

David Schull or Andrea Flynn, Ph.D.

Russo Partners

(212) 845-4271

(646) 942-5631

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[andrea.flynn@russopartnersllc.com](mailto:andrea.flynn@russopartnersllc.com)

Investor Relations Contact:

Sarah McCabe

Stern Investor Relations, Inc.

(212) 362-1200

sarah@sternir.com